Immuron Ltd. is a biopharmaceutical company, which focuses on the development and commercialization of a novel class of specifically targeted polyclonal antibodies. The company operates through two segments: Research and development (R&D), and Hyperimmune products. The R&D segment is focused on R&D projects performed in Australia and the United States. Hyperimmune products segment is engaged in Travelan and Protectyn activities which occur predominantly in Australia, the United States and Canada. Its flagship products consist of Travelan and Protectyn. Travelan is an orally administered passive immunotherapy that prophylactically reduces the likelihood of contracting traveler’s diarrhea and is sold in pharmacies throughout Australia. Protectyn is sold online and in health practitioner clinics and is marketed as an immune supplement to help maintain a healthy digestive function and liver. Its clinical programs include Travelan (IMM-124E), and IMM-529.
IMRN stock price ended at $0.82 on 星期五, after rising 5.13%
On the latest trading day Feb 06, 2026, the stock price of IMRN rose by 5.13%, climbing from $0.84 to $0.82. During the session, the stock saw a volatility of 5.00%, with prices oscillating between a daily low of $0.80 and a high of $0.84. Notably, trading volume dropped by 3.4K shares on the last day despite the price increase, which may signal a potential uptick in risk in the near term. A total of 16.9K shares were traded, equating to a market value of approximately $6.6M.